MX2008012576A - Pirimidinas 5-amido sustituidas inhibidoras del virus de inmunodeficiencia humana. - Google Patents

Pirimidinas 5-amido sustituidas inhibidoras del virus de inmunodeficiencia humana.

Info

Publication number
MX2008012576A
MX2008012576A MX2008012576A MX2008012576A MX2008012576A MX 2008012576 A MX2008012576 A MX 2008012576A MX 2008012576 A MX2008012576 A MX 2008012576A MX 2008012576 A MX2008012576 A MX 2008012576A MX 2008012576 A MX2008012576 A MX 2008012576A
Authority
MX
Mexico
Prior art keywords
substituted pyrimidines
amido substituted
hiv inhibiting
hiv
inhibiting
Prior art date
Application number
MX2008012576A
Other languages
English (en)
Inventor
Jerome Emile Georges Guillemont
Mikael Paugam
Bruno Francois Marie Delest
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of MX2008012576A publication Critical patent/MX2008012576A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Esta invención se refiere a derivados de pirimidina de la fórmula: (ver formula (I)) que tienen propiedades de inhibición de la duplicación del virus de inmunodeficiencia humana VIH;: la preparación de los mismos y composiciones farmacéuticas que comprenden estos compuestos.
MX2008012576A 2006-03-30 2007-03-30 Pirimidinas 5-amido sustituidas inhibidoras del virus de inmunodeficiencia humana. MX2008012576A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06112044 2006-03-30
PCT/EP2007/053111 WO2007113254A1 (en) 2006-03-30 2007-03-30 Hiv inhibiting 5-amido substituted pyrimidines

Publications (1)

Publication Number Publication Date
MX2008012576A true MX2008012576A (es) 2008-10-10

Family

ID=36791649

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008012576A MX2008012576A (es) 2006-03-30 2007-03-30 Pirimidinas 5-amido sustituidas inhibidoras del virus de inmunodeficiencia humana.

Country Status (14)

Country Link
US (2) US8933089B2 (es)
EP (1) EP2004632B1 (es)
JP (1) JP5078986B2 (es)
KR (1) KR20080114741A (es)
CN (1) CN101405283B (es)
AU (1) AU2007233737B2 (es)
BR (1) BRPI0709690B8 (es)
CA (1) CA2645958C (es)
DK (1) DK2004632T3 (es)
ES (1) ES2465666T3 (es)
IL (1) IL193610A (es)
MX (1) MX2008012576A (es)
RU (1) RU2480464C2 (es)
WO (1) WO2007113254A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006035069A1 (en) * 2004-09-30 2006-04-06 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-substituted pyrimidines
BRPI0516746A (pt) * 2004-09-30 2008-09-23 Tibotec Pharm Ltd 5-heterociclil pirimidinas para inibição de hiv
RU2398768C2 (ru) * 2005-02-18 2010-09-10 Тиботек Фармасьютикалз Лтд. Ингибирующие вич производные 2-(4-цианофениламино)-пиримидин-оксида
DK2004632T3 (da) 2006-03-30 2014-06-16 Janssen R & D Ireland Hiv-inhiberende 5-amidosubstituerede pyrimidiner
AU2007341227C1 (en) * 2006-12-29 2013-08-29 Janssen Sciences Ireland Uc HIV inhibiting 6-substituted pyrimidines
ES2523863T3 (es) * 2006-12-29 2014-12-02 Janssen R&D Ireland Pirimidinas 5,6-sustituidas inhibidoras del VIH
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
PT2323993E (pt) 2008-04-16 2015-10-12 Portola Pharm Inc 2,6-diamino-pirimidina-5-il-carboxamidas como inibidores de quinasses syk ou jak
KR101956261B1 (ko) 2008-05-21 2019-03-08 어리어드 파마슈티칼스, 인코포레이티드 키나아제 억제제로서 포스포러스 유도체
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
KR101892989B1 (ko) 2008-06-27 2018-08-30 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
WO2011146313A1 (en) 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
JP6068340B2 (ja) 2010-08-10 2017-01-25 セルジーン アヴィロミクス リサーチ， インコーポレイテッド Ｂｔｋ阻害剤のベシル酸塩
EP2635284B1 (en) 2010-11-01 2019-12-18 Celgene CAR LLC Heterocyclic compounds and uses thereof
JP5956999B2 (ja) 2010-11-01 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ヘテロアリール化合物およびその使用
JP5957003B2 (ja) 2010-11-10 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド 変異体選択的ｅｇｆｒ阻害剤およびその使用
JP5999177B2 (ja) 2011-05-04 2016-09-28 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
KR102063098B1 (ko) 2011-10-03 2020-01-08 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 암 치료를 위한 피롤로피리미딘 화합물
TW201325593A (zh) 2011-10-28 2013-07-01 Celgene Avilomics Res Inc 治療布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶疾病或病症之方法
IN2014CN04065A (es) 2011-11-23 2015-09-04 Portola Pharm Inc
KR102081042B1 (ko) 2012-03-15 2020-02-26 셀젠 카르 엘엘씨 상피 성장 인자 수용체 키나제 억제제의 고체 형태
CA2866857C (en) 2012-03-15 2021-03-09 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
EP2852579A4 (en) 2012-05-22 2015-12-30 Univ North Carolina PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER
CN104718201A (zh) 2012-06-12 2015-06-17 艾伯维公司 吡啶酮和哒嗪酮衍生物
WO2014062774A1 (en) 2012-10-17 2014-04-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
AU2013341195B2 (en) * 2012-11-08 2017-09-21 Bristol-Myers Squibb Company Alkyl amide-substituted pyrimidine compounds useful in the modulation of IL-12, IL-23 and/or IFNalpha
US9771330B2 (en) 2012-11-27 2017-09-26 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
EP2935226A4 (en) 2012-12-21 2016-11-02 Celgene Avilomics Res Inc HETEROARYL COMPOUNDS AND USES THEREOF
TW201446745A (zh) 2013-02-08 2014-12-16 Celgene Avilomics Res Inc Ｅｒｋ抑制劑及其用途
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
CN103483272B (zh) * 2013-09-29 2015-10-21 山东大学 间二芳烃-多取代嘧啶类衍生物及其制备方法与应用
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2015157122A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrazolopyrimidine compounds
US9988374B2 (en) 2014-08-11 2018-06-05 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
WO2016025561A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Forms and compositions of an erk inhibitor
AU2015374231B2 (en) 2014-12-31 2020-07-23 Angion Biomedica Corp. Methods and agents for treating disease
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
CN106967047A (zh) * 2017-03-29 2017-07-21 山东大学 一种取代二芳基烟酰胺类衍生物及其制备方法与应用
TW202229270A (zh) * 2020-12-02 2022-08-01 大陸商深圳微芯生物科技股份有限公司 羥肟酸酯化合物、其製備方法及其應用
CN117186070A (zh) * 2022-06-01 2023-12-08 深圳微芯生物科技股份有限公司 羟肟酸酯化合物及其盐的结晶形式与制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
CZ154398A3 (cs) 1995-11-23 1998-08-12 Janssen Pharmaceutica N.V. Pevné směsi cyklodextrinů připravené vytlačováním taveniny
NO311614B1 (no) 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
DK0945443T3 (da) 1998-03-27 2003-06-02 Janssen Pharmaceutica Nv HIV-hæmmende pyrimidinderivater
EP0945447A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
US6459731B1 (en) * 1998-08-28 2002-10-01 Lucent Technologies Inc. Technique for video communications using a coding-matched filter arrangement
UA70966C2 (uk) * 1998-11-10 2004-11-15 Янссен Фармацевтика Н.В. Піримідини, що інгібують реплікацію віл
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
JP5230050B2 (ja) 2000-05-08 2013-07-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖ複製阻害剤
NZ526471A (en) 2000-12-21 2005-08-26 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
TW200400034A (en) 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
EP1594870B1 (en) 2002-11-15 2011-05-11 Tibotec Pharmaceuticals Substituted indolepyridinium as anti-infective compounds
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US7504396B2 (en) * 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
BRPI0516746A (pt) 2004-09-30 2008-09-23 Tibotec Pharm Ltd 5-heterociclil pirimidinas para inibição de hiv
BRPI0515935B8 (pt) 2004-09-30 2021-05-25 Janssen Sciences Ireland Uc pirimidinas heterociclil- ou 5-carbo substituídas para inibição de hiv, e composição farmacêutica
WO2006035069A1 (en) * 2004-09-30 2006-04-06 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-substituted pyrimidines
DK2004632T3 (da) 2006-03-30 2014-06-16 Janssen R & D Ireland Hiv-inhiberende 5-amidosubstituerede pyrimidiner
AU2007341227C1 (en) 2006-12-29 2013-08-29 Janssen Sciences Ireland Uc HIV inhibiting 6-substituted pyrimidines
ES2523863T3 (es) 2006-12-29 2014-12-02 Janssen R&D Ireland Pirimidinas 5,6-sustituidas inhibidoras del VIH

Also Published As

Publication number Publication date
BRPI0709690A2 (pt) 2011-07-19
ES2465666T3 (es) 2014-06-06
EP2004632A1 (en) 2008-12-24
WO2007113254A1 (en) 2007-10-11
US9573942B2 (en) 2017-02-21
EP2004632B1 (en) 2014-03-12
BRPI0709690B8 (pt) 2021-05-25
KR20080114741A (ko) 2008-12-31
CN101405283A (zh) 2009-04-08
CA2645958A1 (en) 2007-10-11
CA2645958C (en) 2014-11-04
AU2007233737B2 (en) 2012-11-29
DK2004632T3 (da) 2014-06-16
US20100168104A1 (en) 2010-07-01
JP2009531394A (ja) 2009-09-03
CN101405283B (zh) 2014-06-18
RU2008143001A (ru) 2010-05-10
US20150099749A1 (en) 2015-04-09
BRPI0709690B1 (pt) 2020-09-29
AU2007233737A1 (en) 2007-10-11
JP5078986B2 (ja) 2012-11-21
IL193610A0 (en) 2009-05-04
US8933089B2 (en) 2015-01-13
RU2480464C2 (ru) 2013-04-27
IL193610A (en) 2014-01-30

Similar Documents

Publication Publication Date Title
MX2008012576A (es) Pirimidinas 5-amido sustituidas inhibidoras del virus de inmunodeficiencia humana.
IL193725A0 (en) Hiv inhibiting 5-(hydroxymethylene and aminomethylene) substituted pyrimidines
EA201000777A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
WO2008127364A3 (en) Antiviral compounds and use thereof
WO2009111653A3 (en) Antiviral therapeutic agents
WO2008089105A3 (en) Antiviral nucleoside analogs
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
MX2009000884A (es) Derivados de piridizinona.
WO2008031556A3 (en) 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions
EP2041159B8 (en) Macrocyclic compounds as antiviral agents
WO2008002959A3 (en) Hiv integrase inhibitors
MXPA05008866A (es) Pirimidinas sustituidas con indano inhibidoras de la replicacion del virus de inmunodeficiencia humana.
TW200738728A (en) HIV integrase inhibitors
TW200716614A (en) Substituted arylpyrazoles
MX2009005363A (es) Pirimidinas y su uso como antagonistas del receptor cxcr2.
WO2007067506A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
WO2012065963A3 (en) Antiviral condensed heterocyclic compounds
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
CL2008002243A1 (es) Compuestos derivados de 2-pirazolamino-1,3,5-triazina, inhibidores de kinasa jak; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
WO2007059125A3 (en) Hiv integrase inhibitors
WO2009016498A8 (en) Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
WO2007065595A3 (en) Xanthine derivatives, processes for preparing them and their uses
MX2009008495A (es) Novedosos analogos de nucleosidos para el tratamiento de infecciones virales.
WO2006097617A3 (fr) Nouveaux derives dihydropyrimidines et leur utilisation comme agents anti-cancereux

Legal Events

Date Code Title Description
FG Grant or registration